ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.